A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects
Latest Information Update: 27 Oct 2023
At a glance
- Drugs Itepekimab (Primary) ; Itepekimab (Primary)
- Indications Inflammation
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 12 Sep 2023 Results assessing Pharmacokinetics of Subcutaneous Itepekimab Injection With an Autoinjector Device or Prefilled Syringe presented at the 2023 American College of Clinical Pharmacology Annual Meeting
- 06 Nov 2017 Status changed from active, no longer recruiting to completed.
- 19 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Sep 2017.